The association of plasma GDF11/MSTN levels with cardiovascular outcomes and overall deaths in humans was also reported using SOMAmer technology, which revealed that in patients with stable ischemic heart disease, increased GDF11/MSTN levels were associated with decreased rates of cardiovascular events, left ventricular hypertrophy, and overall death87. Here, GDF11 is linked to left ventricular hypertrophy.